Clinical trial · Interventional
Losartan in Prevention of Radiation-Induced Heart Failure
The Role of Losartan in the Prevention of Early Structural Changes Associated With Radiation-Induced Heart Failure
NCT05607017CI-TRIAL-00107388completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: * Losartan * Radiation Therapy (standard of care)
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Myocardial Fibrosis | — | UNRESOLVED | — |
| Radiation-Induced Fibrosis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Losartan | Drug | — | UNRESOLVED |
| Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiation Therapy and Losartan
- description
- Participants will receive radiation therapy 5x weekly over 1-6 weeks. Participants will receive Losartan 1x daily during radiation therapy and for up to 6 months afterward then be followed for 1 year
- interventionNames
- Drug: Losartan
- Radiation: Radiation Therapy
Primary outcomes (1)
- measure
- Extracellular Volume (ECV) of Myocardial Fibrosis
- timeFrame
- 6 months
- description
- The primary endpoint is detectable decrease in extracellular volume as measured by cardiac MRI
Secondary outcomes (1)
- measure
- Serum cardiac biomarker
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: -\>18 years of age * Non-metastatic Breast Cancer patients who are scheduled to receive conventional left breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs) * Prior chemotherapy is permitted * Patients must have Left-sided Breast Cancer * Ability to understand and the willingness to sign a written informed consent document * No contraindication to MRI Exclusion Criteria: * Person who is pregnant or breastfeeding. * Patient unable to swallow oral medication. * Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity * Patients already receiving ACE/ARBs. * Patients with a history of allergic reactions to Losartan biosimilars.
References
Publications (0)
Data not yet available
No reference posted for this study.